Search Results

You are looking at 11 - 20 of 58 items for :

  • Framingham risk score x
Clear All
Open access

Manta Andrei, Maștaleru Alexandra, Oancea Andra, Anghel Razvan Constantin, Roca Mihai, Leon-Constantin Maria Magdalena and Mitu Florin

the growing epidemic and its associated pathologies. Obes Rev. 2015;16(1):1-12. 4. Wang H, Sun Y, Yi X, Zhang L. Evaluation of the Framingham risk score and pooled cohort risk equation for prediction of cardiovascular risk in low resource areas: Insights from Asian rural population. Int J Cardiol. 2018;265:237. 5. Fonseca FAH, Izar MCO. Prevalence of Metabolic Syndrome and Framingham Risk Score in Vegetarian and Omnivorous Apparently Healthy Men. Arq Bras Cardiol. 2018;110(5):438-439. 6. Vanavanan S, Srisawasdi P, Rochanawutanon M, Kumproa N

Open access

Grazyna Sypniewska, Katarzyna Bergmann, Magdalena Krintus, Marek Kozinski and Jacek Kubica

Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008; 51: 1512-24. Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small lowdensity lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113: 20-9. Chan DC, Watts GF. Apolipoproteins as markers and managers of coronary risk. QJM 2006; 99: 277-87. Eremić N, Đerić M. Evaluation of coronary risk score applications in 10-yaer coronary

Open access

Dragan Vasiljevic, Aleksandra Tomic-Lucic, Sandra Zivanovic, Mirjana Milosavljevic, Snezana Radovanovic, Nebojsa Andjelkovic, Dragan Djuric and Mirjana Veselinovic

- rheumatoid factor VAS - visual analogue score REFERENCES 1. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010; 69(2): 312-325. 2. Martin-Martinez MA, Gonzalez-Juanatey C, Castaneda S, Llorca J, et al. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. Semin Arthritis Rheum. 2014; 44(1): 1

Open access

Oana Albai and Romulus Timar

European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Risk of Cardiovascular Disease): I. Methodology and objectives. Diabetologia 47: 566-570, 2004. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 165: 2644-2650, 2005. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to

Open access

Volodymyr Pankiv and Ivan Pankiv

body mass index in an urban black community in Mangaung, South Africa. Afr J Prm Health Care Fam Med 8(1): 1210, 2016. 5. Wang S. Epidemiology of vitamin D in health and disease. Nutr Res Rev 22(2): 188-203, 2009 6. Truesdell D, Shin H, Liu PY, Ilich IZ. Vitamin D status and Framingham Risk Score in overweight postmenopausal women. J Womens Health 20(9): 1341- 1348, 2011. 7. Wortsman J, Matsuoka LY, Chen TC et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72(3): 690-693, 2000. 8

Open access

Vesna Vuković-Dejanović, Nataša Bogavac-Stanojević, Slavica Spasić, Vesna Spasojević-Kalimanovska, Dimitra Kalimanovska-Oštrić, Mirko Topalović and Zorana Jelić-Ivanović

coronary artery disease by using Framingham Risk Score (FRS). J An Bio-Sci 2011; 34: 324–30. 35. Koenig W, Löwel H, Baumert J, Meisinger C. Baumert and Christa Meisinger. C-Reactive Protein modulates risk prediction based on the Framingham Score: Implications for future risk assessment: Results from a large cohort study in Southern Germany. Circulation 2004; 109: 1349–53. 36. Cristell N, Cianflone D, Durante A, Ammirati E, Vanuzzo D, Banfi M, et al. High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation

Open access

Jolita Badarienė, Jelena Čelutkienė, Dovilė Petrikonytė, Jūratė Balsytė, Egidija Rinkūnienė, Ligita Ryliškytė, Vilma Dženkevičiūtė, Alma Čypienė, Romualdas Kizlaitis, Roma Puronaitė and Aleksandras Laucevičius

References [1] Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 2010;35:72–115. [2] WHO, The top 10 causes of death. WHO n.d. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/index2.html [accessed March 20, 2015]. [3] Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005

Open access

Zofia Radikova, Adela Penesova, Miroslav Vlcek, Andrea Havranova, Monika Sivakova, Pavel Siarnik, Ingrid Zitnanova, Richard Imrich, Branislav Kollar and Peter Turcani

Framingham risk score of coronary heart disease in middle-aged men with increased non-HDL cholesterol. Int J Cardiol 168, 3853–3858, 2013. Jorissen W, Wouters E, Bogie JF, Vanmierlo T, Noben JP, Sviridov D, Hellings N, Somers V, Valcke R, Vanwijmeersch B, Stinissen P, Mulder MT, Remaley AT, Hendriks JJ. Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL. Sci Rep 7, 43410, 2017. Jorissen W, Vanmierlo T, Wens I, Somers V, Van Wijmeersch B, Bogie JF, Remaley AT, Eijnde BO, Hendriks JJA. Twelve Weeks of

Open access

Ivo S. Petrov, Arman Sh. Postadzhiyan, Mariya P. Tokmakova, Lyudmila G. Kitova, Svetlin N. Tsonev, Janet Addison, Reneta T. Petkova and Vasil I. Lachev

, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidemias: the Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818. 9. Conroy R, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003. 10. D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study

Open access

Marijan Bosevski

? Int J Cardiol. 2009 Jan 9;131(2):290-2. 12. Smink PA, Lambers Heerspink HJ, Gansevoort RT, de Jong PE, Hillege HL, Bakker SJ, de Zeeuw D. Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. Am J Kidney Dis. 2012 Nov;60(5):804-11 13. Chang A, Kramer H. Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney diseaseand cardiovascular disease risk prediction. Nephron Clin Pract. 2011;119(2):c171-7; 14. Dzekova